Selected data models

You must log in to select data models for download or further analysis.

5 Search results.
Relevance Rating New first Old first

Follow-Up Treatment GOAL Trial B-cell Lymphoma NCT02499003

- 1/1/18 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Admininstrative data, Follow-Up Lymphoma Treatment
NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma. Study part: Follow-Up Lymphoma Treatment. Visit: All visits. Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Post Treatment Response - Follow-Up

- 7/25/18 - 1 form, 10 itemgroups, 39 items, 1 language
Itemgroups: Administrative Data, Diagnostic Imaging, Head/Neck, Diagnostic Imaging; Chest, Diagnostic Imaging, Abdomen, Diagnostic Imaging, Pelvis, Diagnostic Imaging, Other, Bone Marrow Biopsy, Measurable Lymphoma Disease, Non-Measurable Disease, Response to treatment
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Long-Term Follow-Up for Survival & Disease Status

- 7/25/18 - 1 form, 6 itemgroups, 17 items, 1 language
Itemgroups: Default Itemgroup, Additional therapy for NHL since Anti-B1, Myelodysplasia, Malignancy, Thyroid medication, Comments
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin This form is to be completed every 6 months once the patient has entered long-term follow-up.

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Long-Term Follow-Up for Survival & Disease Status

- 7/10/18 - 1 form, 7 itemgroups, 23 items, 1 language
Itemgroups: Administrative Data, Additional therapy for NHL since the last LTFU, Myelodysplasia, AML, Malignancy, TSH measurement, HAMA
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin This form is to be completed every 6 months once the patient has entered long-term follow-up.

Patient Status GOAL Trial B-cell Lymphoma NCT02499003

- 12/31/17 - 1 form, 4 itemgroups, 11 items, 1 language
Itemgroups: Administrative data, Patient status, patient alive, Patient deceased
NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial